Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$7.09 USD
-1.31 (-15.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EBS 7.09 -1.31(-15.60%)
Will EBS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
Repligen (RGEN) Q2 Earnings Meet Estimates
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Other News for EBS
Emergent Biosolutions (EBS) Receives a Buy from Benchmark Co.
Emergent BioSolutions rises 34.3%
Emergent BioSolutions falls -38.5%
Disney, Airbnb dip despite quarterly beats: Morning Buzz
Emergent BioSolutions falls -38.1%